Table 1 Distribution of TTS by cohort demographic and clinical characteristics within subtypes
HR + /HER2- | HER2 + | HR-/HER2- | ||||
|---|---|---|---|---|---|---|
n (%) | Median (Q1–Q3) | n (%) | Median (Q1–Q3) | n (%) | Median (Q1–Q3) | |
28,332 (100) | 29 (21–42) | 3,226 (100) | 29 (20–41) | 2,690 (100) | 29 (20–42) | |
Age | ||||||
< 70 | 7,766 (27.4) | 31 (21–44) | 919 (28.5) | 29 (20–42) | 637 (23.7) | 29 (20–42) |
70- 74 | 8,678 (30.6) | 29 (21–42) | 914 (28.3) | 29 (20–41) | 782 (29.1) | 29 (20–42) |
75- 79 | 6,254 (22.1) | 29 (21–42) | 693 (21.5) | 28 (20–40) | 595 (22.1) | 29 (20–43) |
80–84 | 3,687 (13.0) | 28 (20–41) | 439 (13.6) | 29 (20–41) | 383 (14.2) | 28 (20–41) |
85 + | 1,947 (6.9) | 28 (20–42) | 261 (8.1) | 28 (20–40) | 293 (10.9) | 29 (21–40) |
Race/ethnicity | ||||||
White | 25,206 (89.0) | 29 (21–42) | 2,775 (86.0) | 28 (20–41) | 2,234 (83) | 28 (20–41) |
Black | 1,526 (5.4) | 34 (23–48) | 230 (7.1) | 31 (22–51) | 320 (11.9) | 36 (23–51) |
Other | 1,600 (5.6) | 33 (22–44) | 221 (6.9) | 30 (21–43) | 136 (5.1) | 29 (20–43) |
Charlson comorbidity index | ||||||
0 | 16,102 (56.8) | 29 (21–42) | 1,738 (53.9) | 28 (19–40) | 1,411 (52.5) | 28 (20–41) |
1 | 6,820 (24.1) | 29 (21–42) | 794 (24.6) | 29 (20–41) | 650 (24.2) | 28 (20–42) |
2 + | 5,410 (19.1) | 31 (21–45) | 694 (21.5) | 32 (22–44) | 629 (23.4) | 31 (21–45) |
Year of diagnosis | ||||||
2010 | 3,021 (10.7) | 27 (19–38) | 370 (11.5) | 25 (17–37) | 348 (12.9) | 28 (19–40) |
2011 | 3,173 (11.2) | 28 (19–40) | 367 (11.4) | 27 (18–36) | 338 (12.6) | 27 (19–41) |
2012 | 3,407 (12.0) | 29 (20–41) | 397 (12.3) | 28 (18–38) | 371 (13.8) | 27 (19–37) |
2013 | 3,553 (12.5) | 29 (20–42) | 397 (12.3) | 28 (20–42) | 324 (12.0) | 29 (20–43) |
2014 | 3,564 (12.6) | 29 (21–42) | 424 (13.1) | 30 (21–42) | 345 (12.8) | 28 (21–42) |
2015 | 3,780 (13.3) | 31 (22–43) | 463 (14.4) | 29 (21–42) | 311 (11.6) | 32 (22–43) |
2016 | 3,998 (14.1) | 32 (22–44) | 417 (12.9) | 31 (22–43) | 321 (11.9) | 31 (21–45) |
2017 | 3,836 (13.5) | 33 (22–47) | 391 (12.1) | 32 (24–46) | 332 (12.3) | 31(22–43) |
SEER Stage | ||||||
Local | 22,874 (80.7) | 29 (21–42) | 2,342 (72.6) | 28 (20–41) | 2,152 (80.0) | 29 (20–42) |
Regional lymph node involvement | 5,458 (19.3) | 30 (21–44) | 884 (27.4) | 29 (20–42) | 538 (20.0) | 29 (20–44) |
Histology | ||||||
Ductal | 21,086 (74.4) | 29 (21–42) | 2,849 (88.3) | 28 (20–41) | 2,312 (86.0) | 29 (20–42) |
Lobular | 5,736 (20.2) | 32 (22–44) | 282 (8.7) | 33 (23–49) | 104 (3.9) | 29 (19–45) |
Other | 1,510 (5.3) | 29 (21–41) | 95 (2.9) | 30 (18–43) | 274 (10.2) | 31 (21–44) |
Grade | ||||||
1 | 9,615 (33.9) | 29 (21–42) | 240 (7.4) | 28 (20–40.5) | 86 (3.2) | 28 (19–43) |
2 | 14,745 (52.1) | 30 (21–43) | 1,244 (38.6) | 30(20–42) | 661 (24.6) | 31 (21–43) |
3 or 4 | 3,972 (14.0) | 28 (20–42) | 1,742 (54) | 28 (20–41) | 1,943 (72.2) | 28 (20–41) |
Type of surgery | ||||||
Breast conserving | 19,730 (69.6) | 29 (21–41) | 1,775 (55) | 28 (20–40) | 1,602 (59.6) | 28 (21–41) |
Mastectomy | 7,179 (25.4) | 29 (20–43) | 1,265 (39.2) | 28 (20–41) | 982 (36.5) | 29 (19–43) |
Mastectomy w/reconstruction | 1,423 (5.0) | 45 (33–61) | 186 (5.8) | 44 (32–60) | 106 (3.9) | 41 (27–60) |
Chemo/targeted therapy | ||||||
No | 22,354 (78.9) | 29 (21–42) | 1,030 (31.9) | 29 (21–42) | 1,171 (43.5) | 30 (21–43) |
Yes | 5,978 (21.1) | 29 (20–42) | 2,196 (68.1) | 29 (20–41) | 1,519 (56.5) | 28 (20–41) |
Radiation | ||||||
No | 9,714 (34.3) | 31 (21–46) | 1,258 (39) | 30 (20–45) | 903 (33.6) | 30 (20–44) |
Yes | 18,618 (65.7) | 29 (21–41) | 1,968 (61) | 28 (20–40) | 1,787 (66.4) | 29 (20–41) |
HR status | ||||||
Negative | 1,200 (37) | 29 (20–42) | 2,690 (100) | |||
Positive | 28,332 (100) | 2,026 (63) | 28 (20–41) | |||
Cause of death | ||||||
Breast cancer | 900 (3.2) | 28 (20–44) | 210 (6.5) | 29 (20–41) | 342 (12.7) | 29 (19–42) |
Other | 2,800 (9.9) | 28 (20–42) | 334 (10.4) | 30 (20–42) | 324 (12.0) | 28 (20–43) |
Censored | 24,632 (86.9) | 30 (21–42) | 2,682 (83.1) | 29 (20–41) | 2,024 (75.3) | 29 (21–42) |